Senti Biosciences Holdings, Inc.
Senti Biosciences, Inc. is a clinical-stage biotechnology company developing next-generation cell and gene therapies using proprietary gene circuit platform technologies. The company's mission centers on creating smarter medicines that can sense inputs, compute decisions, and respond to cellular environments to treat… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Senti Biosciences Holdings, Inc. does
In the company’s own words
Senti Biosciences, Inc. is a clinical-stage biotechnology company developing next-generation cell and gene therapies using proprietary gene circuit platform technologies. The company's mission centers on creating smarter medicines that can sense inputs, compute decisions, and respond to cellular environments to treat incurable diseases.
The company's lead product candidate, SENTI-202, is a potentially first-in-class Logic Gated off-the-shelf CAR-NK cell therapy currently in Phase 1 clinical trials for relapsed or refractory hematologic malignancies, including acute myeloid leukemia. SENTI-202 has received Orphan Drug Designation and Regenerative Medicine Advanced Therapy designation from the FDA. Early clinical data from the Phase 1 trial demonstrated a 50% overall response rate among treated patients, with 42% achieving complete remission or complete remission with incomplete hematologic recovery, and all patients showing a favorable safety profile.
Senti's gene circuit platform comprises four core technology categories: Logic Gating, Multi-Arming, Regulator Dials, and Smart Sensors. These technologies are designed to enhance precision, control, and activity of cell and gene therapies across multiple treatment modalities including NK cells, T cells, tumor infiltrating lymphocytes, stem cells, and in vivo gene therapies. The company's pipeline extends beyond its lead oncology program to include solid tumor cell therapy programs and partnered programs in regenerative medicine.
In August 2023, Senti divested its manufacturing assets and facility to GeneFab, LLC, a newly formed contract manufacturing organization, allowing the company to focus on clinical development while maintaining manufacturing capabilities through service contracts. The company maintains strategic collaborations with BlueRock Therapeutics, a Bayer subsidiary, for regenerative medicine applications and holds exclusive or co-exclusive patent licenses from the National Cancer Institute for FLT3 and CD33 targeting CAR technologies.
Senti qualifies as both a smaller reporting company and an emerging growth company under SEC definitions. The company operates as a clinical-stage enterprise focused on advancing its pipeline through clinical development and establishing value-creating partnerships to expand its technology platform across additional therapeutic modalities and disease areas.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1854270
- SIC
- 2836
Financial performance, year by year
Fiscal 2022–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Senti Biosciences Holdings, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Senti Biosciences Holdings, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Senti Biosciences Holdings, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Senti Biosciences Holdings, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Senti Biosciences Holdings, Inc.'s last four quarterly filings that the numbers alone won't show?”